Healx scientists, in a study led by Erin Oerton, have evaluated different types of biological information for their value of relating diseases to each in other, in a publication that has just appeared in the journal Bioinformatics.
Read the latest news about Healx and our goal to advance treatments for rare diseases.
We are delighted to announce $10 million Series A funding round, led by Balderton Capital. Existing investors, Jonathan Milner and Amadeus Capital Partners also participated in the round.
The Business Weekly article also covers the appointment of Shaun Grady, a leading business development executive at Astra Zeneca, to Healx’s board of directors
Erin Oerton, a PhD student at the University of Cambridge and data scientist at Healx, has won the poster prize for the Systems Medicine track at the 2nd Interdisciplinary Signalling Workshop in Visegrad, Hungary.
Healx Scientist, Dan Mason, develops a machine learning approach to predict effectiveness of combinations of antibiotic treatments.